metastatic/advanced OC (mOC) - 1st line (L1) | metastatic/advanced OC (mOC) - 2nd line (L2) | metastatic/advanced OC (mOC) - maintenance (M) | |||
metastatic/advanced OC (mOC) - 1st line (L1) | mOC - L1 - all population | mOC - L1 - PDL1 positive | metastatic/advanced OC (mOC) - 2nd line (L2) | metastatic/advanced OC (mOC) - maintenance (M) | |
anti-PD-(L)1 | |||||
atezolizumab based treatment | |||||
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | |||||
atezolizumab plus SoC | IMagyn-050 ... | IMagyn-050 ... | |||
avelumab based treatment | |||||
avelumab alone | JAVELIN ovarian 200 ... | ||||
avelumab plus pegylated liposomal doxorubicin | JAVELIN ovarian 200 ... | ||||
avelumab plus SoC | |||||
nivolumab based treatment |